ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Current bid/ask 28 cents?

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Jul 11, 2022 5:46pm

199 Views

Post# 34816429

RE:RE:Current bid/ask 28 cents?

A one-day stock price prediction from over a year ago? Pretty weak.

I'm going to let you in on a secret here, David/azzy; it's you who are arrogant and stupid. Of course, the catch-22 is that you're too stupid to realize it.

But I digress.

Anyhow, looking forward to six months from now when you once again tell us how you bought at the low and sold at the high, and hilariously expect us to believe it.

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks